Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for sitagliptin (S09.003 inhibitor)

Summary Structure Literature Inhibits

(Topics flags: S Structure, K Knockout, I Inhibitor, V Review, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

    2020
  1. Abbas,H.A. and Hegazy,W.A.H.
    Repurposing anti-diabetic drug Sitagliptin as a novel virulence attenuating agent in Serratia marcescens
    PLoS ONE (2020) 15, e0231625-e0231625. PubMed  Europe PubMed DOI  PMC  EPMC  I
  2. Abbas,H.A., Shaldam,M.A. and Eldamasi,D.
    Curtailing quorum sensing in Pseudomonas aeruginosa by sitagliptin
    Curr Microbiol (2020) 77, 1051-1060. PubMed  Europe PubMed DOI  I
  3. Xue,J., Wang,C., Pan,C., Xing,H., Xu,L., Chen,X., Wang,X. and Wang,N.
    Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
    Exp Ther Med (2020) 19, 1356-1362. PubMed  Europe PubMed DOI  PMC  EPMC  I
    4. 2019
  4. Dube,M.P., Chan,E.S., Lake,J.E., Williams,B., Kinslow,J., Landay,A., Coombs,R.W., Floris-Moore,M., Ribaudo,H.J. and Yarasheski,K.E.
    A randomized, double-blinded, placebo-controlled trial of sitagliptin for reducing inflammation and immune activation in treated and suppressed human immunodeficiency virus infection
    Clin Infect Dis (2019) 69, 1165-1172. PubMed  Europe PubMed DOI  I
  5. Hollande,C., Boussier,J., Ziai,J., Nozawa,T., Bondet,V., Phung,W., Lu,B., Duffy,D., Paradis,V., Mallet,V., Eberl,G., Sandoval,W., Schartner,J.M., Pol,S., Barreira da Silva,R. and Albert,M.L.
    Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth
    Nat Immunol (2019) 20, 257-264. PubMed  Europe PubMed DOI  I
  6. Li,L., Lian,X., Wang,Z., Zheng,J., Liu,J., Chu,Y., Teng,Y. and Zhang,Z.
    The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-beta/Smad signal pathway
    Pharmazie (2019) 74, 239-242. PubMed  Europe PubMed DOI  I
  7. Stofella,N.C.F., Veiga,A., Oliveira,L.J., Montin,E.F., Andreazza,I.F., Carvalho Filho,M.A.S., Bernardi,L.S., Oliveira,P.R. and Murakami,F.S.
    Solid-state characterization of different crystalline forms of sitagliptin
    Materials (Basel) (2019) 12 PubMed  Europe PubMed DOI  I
    8. 2018
  8. Al-Awar,A., Almasi,N., Szabo,R., Takacs,I., Murlasits,Z., Szucs,G., Torok,S., Posa,A., Varga,C. and Kupai,K.
    Novel potentials of the DPP-4 inhibitor sitagliptin against ischemia-reperfusion (I/R) injury in rat ex-vivo heart model
    Int J Mol Sci (2018) 19 PubMed  Europe PubMed DOI  I
  9. Kawasaki,T., Chen,W., Htwe,Y.M., Tatsumi,K. and Dudek,S.M.
    DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice
    Am J Physiol Lung Cell Mol Physiol (2018) 315, L834-L834. PubMed  Europe PubMed DOI  I
  10. Koyani,C.N., Trummer,C., Shrestha,N., Scheruebel,S., Bourgeois,B., Plastira,I., Kickmaier,S., Sourij,H., Rainer,P.P., Madl,T., Sattler,W., Pelzmann,B., Malle,E. and von Lewinski,D.
    Saxagliptin but not sitagliptin inhibits CaMKII and PKC via DPP9 inhibition in cardiomyocytes
    Front Physiol (2018) 9, 1622-1622. PubMed  Europe PubMed DOI  PMC  EPMC  I
  11. Luippold,G., Mark,M., Klein,T., Amann,K. and Daniel,C.
    Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin
    Diabetes Res Clin Pract (2018) 143, 199-203. PubMed  Europe PubMed DOI  I
  12. Shih,C.M., Huang,C.Y., Huang,C.Y., Wang,K.H., Wei,P.L., Chang,Y.J., Fong,T.H., Pan,J.L. and Lee,A.W.
    A dipeptidyl peptidase-4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity
    Exp Dermatol (2018) 27, 1134-1141. PubMed  Europe PubMed DOI  I
    13. 2017
  13. Awata,T., Shimada,A., Maruyama,T., Oikawa,Y., Yasukawa,N., Kurihara,S., Miyashita,Y., Hatano,M., Ikegami,Y., Matsuda,M., Niwa,M., Kazama,Y., Tanaka,S. and Kobayashi,T.
    Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive Type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S)
    Diabetes Ther (2017) 8, 1123-1134. PubMed  Europe PubMed DOI  I
  14. Hernandez,C., Bogdanov,P., Sola-Adell,C., Sampedro,J., Valeri,M., Genis,X., Simo-Servat,O., Garcia-Ramirez,M. and Simo,R.
    Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes
    Diabetologia (2017) 60, 2285-2298. PubMed  Europe PubMed DOI  I
    15. 2016
  15. Arulmozhiraja,S., Matsuo,N., Ishitsubo,E., Okazaki,S., Shimano,H. and Tokiwa,H.
    Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs - an ab initio fragment molecular orbital study
    PLoS ONE (2016) 11, e0166275-e0166275. PubMed  Europe PubMed DOI  I
  16. de Almeida Salles,T., Zogbi,C., de Lima,T.M., de Godoi Carneiro,C., Garcez,A.T., Barbeiro,H.V., Antonio,E.L., Dos Santos,L., da Costa Pereira,A., Tucci,P.J., de Paula Faria,D., Soriano,F.G. and Girardi,A.C.
    The contributions of dipeptidyl peptidase IV to inflammation in heart failure
    Am J Physiol Heart Circ Physiol (2016) 310, H1760-H1772. PubMed  Europe PubMed DOI  I
  17. El-Agamy,D.S., Abo-Haded,H.M. and Elkablawy,M.A.
    Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats
    Exp Biol Med (Maywood) (2016) 241, 1577-1587. PubMed  Europe PubMed DOI  I
  18. Katsuno,T., Ikeda,H. and Namba,M.
    Medium-term effect of add-on therapy with the DPP-4 inhibitor, sitagliptin, in insulin-treated Japanese patients with type 2 diabetes mellitus
    Diabetes Ther (2016) 7, 309-320. PubMed  Europe PubMed DOI  I
  19. Kondo,Y., Harada,N., Hamasaki,A., Kaneko,S., Yasuda,K., Ogawa,E., Harashima,S., Yoneda,H., Fujita,Y., Kitano,N., Nakamura,Y., Matsuo,F., Shinji,M., Hinotsu,S., Nakayama,T. and Inagaki,N.
    Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
    Diabetol Metab Syndr (2016) 8, 15-15. PubMed  Europe PubMed DOI  PMC  EPMC  I
  20. Shi,S., Kanasaki,K. and Koya,D.
    Linagliptin but not Sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
    Biochem Biophys Res Commun (2016) 471, 184-190. PubMed  Europe PubMed DOI  I
    21. 2015
  21. Bachor,T.P., Marquioni-Ramella,M.D. and Suburo,A.M.
    Sitagliptin protects proliferation of neural progenitor cells in diabetic mice
    Metab Brain Dis (2015) 30, 885-893. PubMed  Europe PubMed DOI  I
  22. Barreira da Silva,R., Laird,M.E., Yatim,N., Fiette,L., Ingersoll,M.A. and Albert,M.L.
    Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
    Nat Immunol (2015) 16, 850-858. PubMed  Europe PubMed DOI  I
  23. Gilibili,R.R., Bhamidipati,R.K., Mullangi,R. and Srinivas,N.R.
    Retrospective and prospective human intravenous and oral pharmacokinetic projection of dipeptidyl peptidase-IV inhibitors using simple allometric principles - case studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin
    J Pharm Pharm Sci (2015) 18, 434-448. PubMed  Europe PubMed  I
  24. Kothny,W., Lukashevich,V., Foley,J.E., Rendell,M.S. and Schweizer,A.
    Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
    Diabetologia (2015) 58, 2020-2026. PubMed  Europe PubMed DOI  I
  25. Lee,M. and Rhee,M.K.
    Sitagliptin for type 2 diabetes: a 2015 update
    Expert Rev Cardiovasc Ther (2015) 13, 597-610. PubMed  Europe PubMed DOI  I
  26. Lee,T.M., Chen,W.T. and Chang,N.C.
    Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase A-dependent pathway in infarcted hearts
    Circ J (2015) 79, 2461-2470. PubMed  Europe PubMed DOI  I
  27. Nader,M.A.
    Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma
    Int Immunopharmacol (2015) 29, 761-769. PubMed  Europe PubMed DOI  U  I
  28. Scheen,A.J.
    Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
    Expert Opin Drug Saf (2015) 14, 505-524. PubMed  Europe PubMed DOI  I
  29. Sharma,A.N., Pise,A., Sharma,J.N. and Shukla,P.
    Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats
    Metab Brain Dis (2015) 30, 659-667. PubMed  Europe PubMed DOI  I
  30. Tsai,T.H., Sun,C.K., Su,C.H., Sung,P.H., Chua,S., Zhen,Y.Y., Leu,S., Chang,H.W., Yang,J.L. and Yip,H.K.
    Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction
    J Hypertens (2015) 33, 1001-1013. PubMed  Europe PubMed DOI  I
    31. 2014
  31. Chakraborty,C., Hsu,M.J. and Agoramoorthy,G.
    Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with sitagliptin and inhibitor diprotin-A
    Cell Biochem Biophys (2014) 70, 907-922. PubMed  Europe PubMed DOI  I
  32. Chua,S., Lee,F.Y., Tsai,T.H., Sheu,J.J., Leu,S., Sun,C.K., Chen,Y.L., Chang,H.W., Chai,H.T., Liu,C.F., Lu,H.I. and Yip,H.K.
    Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats
    J Transl Med (2014) 12, 357-357. PubMed  Europe PubMed DOI  I
  33. Juang,J.H., Kuo,C.H., Liu,Y.H., Chang,H.Y. and Chen,C.T.
    Effects of dipeptidyl peptidase-4 inhibition with MK-0431 on syngeneic mouse islet transplantation
    Int J Endocrinol (2014) 2014, 795283-795283. PubMed  Europe PubMed DOI  PMC  EPMC  I
  34. Marques,C., Mega,C., Goncalves,A., Rodrigues-Santos,P., Teixeira-Lemos,E., Teixeira,F., Fontes-Ribeiro,C., Reis,F. and Fernandes,R.
    Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals
    Mediators Inflamm (2014) 2014, 538737-538737. PubMed  Europe PubMed DOI  PMC  EPMC  I
  35. McCormick,L.M., Kydd,A.C., Read,P.A., Ring,L.S., Bond,S.J., Hoole,S.P. and Dutka,D.P.
    Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease
    Circ Cardiovasc Imaging (2014) 7, 274-281. PubMed  Europe PubMed DOI  I
  36. Murai,K., Katsuno,T., Miyagawa,J., Matsuo,T., Ochi,F., Tokuda,M., Kusunoki,Y., Miuchi,M. and Namba,M.
    Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data
    Drugs R D (2014) 14, 301-308. PubMed  Europe PubMed DOI  I
  37. Plosker,G.L.
    Sitagliptin: a review of its use in patients with type 2 diabetes mellitus
    Drugs (2014) 74, 223-242. PubMed  Europe PubMed DOI  I
  38. Robinson,M.V., Mel'nikova,E.V. and Trufakin,V.A.
    Effects of dipeptidyl peptidase IV inhibitor sitagliptin on immunological parameters of lymphocytes in intact animals and animals with experimental autoimmune process
    Bull Exp Biol Med (2014) 158, 66-69. PubMed  Europe PubMed DOI  I
  39. Xiao,C., Dash,S., Morgantini,C., Patterson,B.W. and Lewis,G.F.
    Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans
    Diabetes (2014) 63, 2394-2401. PubMed  Europe PubMed DOI  I
    40. 2013
  40. Aston-Mourney,K., Subramanian,S.L., Zraika,S., Samarasekera,T., Meier,D.T., Goldstein,L.C. and Hull,R.L.
    One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
    Am J Physiol Endocrinol Metab (2013) 305, E475-E484. PubMed  Europe PubMed DOI  I
  41. de Paula e Mancilha,T., de Paula,C.E., Cassella,R.J. and Pacheco,W.F.
    Direct determination of sitagliptin in pharmaceutical formulations and its determination in urine after solid-phase extraction by spectrofluorimetry
    Luminescence (2013) 28, 873-878. PubMed  Europe PubMed DOI  I
  42. Engel,S.S., Round,E., Golm,G.T., Kaufman,K.D. and Goldstein,B.J.
    Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies
    Diabetes Ther (2013) 4, 119-145. PubMed  Europe PubMed DOI  I
  43. Farag,S.S., Srivastava,S., Messina-Graham,S., Schwartz,J., Robertson,M.J., Abonour,R., Cornetta,K., Wood,L., Secrest,A., Strother,R.M., Jones,D.R. and Broxmeyer,H.E.
    In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies
    Stem Cells Dev (2013) 22, 1007-1015. PubMed  Europe PubMed DOI  I
  44. Femia,A.P., Raimondi,L., Maglieri,G., Lodovici,M., Mannucci,E. and Caderni,G.
    Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats
    Int J Cancer (2013) 133, 2498-2503. PubMed  Europe PubMed DOI  I
  45. Garg,K., Tripathi,C.D. and Kumar,S.
    Clinical review of sitagliptin: a DPP-4 inhibitor
    J Assoc Physicians India (2013) 61, 645-649. PubMed  Europe PubMed  I
  46. Goodwin,S.R., Reeds,D.N., Royal,M., Struthers,H., Laciny,E. and Yarasheski,K.E.
    Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study
    J Clin Endocrinol Metab (2013) 98, 743-751. PubMed  Europe PubMed DOI  I
  47. Hage,C., Brismar,K., Efendic,S., Lundman,P., Ryden,L. and Mellbin,L.
    Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities - the BEGAMI study
    J Intern Med (2013) 273, 410-421. PubMed  Europe PubMed DOI  I
  48. Krishnamoorthy,M. and Achary,A.
    Exploration of sitagliptin as a potential inhibitor for the M1 alanine aminopeptidase enzyme in Plasmodium falciparum using computational docking
    Bioinformation (2013) 9, 293-298. PubMed  Europe PubMed DOI  PMC  EPMC  I
  49. McGowan,S.
    Sitagliptin does not inhibit the M1 alanyl aminopeptidase from Plasmodium falciparum
    Bioinformation (2013) 9, 661-662. PubMed  Europe PubMed DOI  PMC  EPMC  I
  50. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
    A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
    Biochem Biophys Res Commun (2013) 434, 191-196. PubMed  Europe PubMed DOI  I
  51. Pintana,H., Apaijai,N., Chattipakorn,N. and Chattipakorn,S.C.
    DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats
    J Endocrinol (2013) 218, 1-11. PubMed  Europe PubMed DOI  I
  52. Shimasaki,T., Masaki,T., Mitsutomi,K., Ueno,D., Gotoh,K., Chiba,S., Kakuma,T. and Yoshimatsu,H.
    The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity
    PLoS ONE (2013) 8, e63626-e63626. PubMed  Europe PubMed DOI  PMC  EPMC  I
  53. Tatosian,D.A., Guo,Y., Schaeffer,A.K., Gaibu,N., Popa,S., Stoch,A., Langdon,R.B. and Kauh,E.A.
    Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Diabetes Ther (2013) 4, 431-442. PubMed  Europe PubMed DOI  I
  54. Teramachi,H., Ohta,H., Tachi,T., Toyoshima,M., Mizui,T., Goto,C. and Tsuchiya,T.
    Pharmacoeconomic analysis of DPP-4 inhibitors
    Pharmazie (2013) 68, 909-915. PubMed  Europe PubMed DOI  I
    55. 2012
  55. Aso,Y., Ozeki,N., Terasawa,T., Naruse,R., Hara,K., Suetsugu,M., Takebayashi,K., Shibazaki,M., Haruki,K., Morita,K. and Inukai,T.
    Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
    Transl Res (2012) 159, 25-31. PubMed  Europe PubMed DOI  I
  56. Derosa,G. and Maffioli,P.
    Dipeptidyl peptidase-4 inhibitors: 3 years of experience
    Diabetes Technol Ther (2012) 14, 350-364. PubMed  Europe PubMed DOI  I
  57. Derosa,G., Carbone,A., D'Angelo,A., Querci,F., Fogari,E., Cicero,A.F. and Maffioli,P.
    A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function
    Expert Opin Pharmacother (2012) 13, 2433-2442. PubMed  Europe PubMed DOI  I
  58. Furukawa,S., Kumagi,T., Miyake,T., Ueda,T., Niiya,T., Nishino,K., Murakami,S., Murakami,M., Matsuura,B. and Onji,M.
    Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature
    Endocr J (2012) 59, 329-333. PubMed  Europe PubMed DOI  I
  59. Gibbs,J.P., Fredrickson,J., Barbee,T., Correa,I., Smith,B., Lin,S.L. and Gibbs,M.A.
    Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results
    J Clin Pharmacol (2012) 52, 1494-1505. PubMed  Europe PubMed DOI  I
  60. Golightly,L.K., Drayna,C.C. and McDermott,M.T.
    Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    Clin Pharmacokinet (2012) 51, 501-514. PubMed  Europe PubMed DOI  I
  61. Goncalves,A., Leal,E., Paiva,A., Teixeira Lemos,E., Teixeira,F., Ribeiro,C.F., Reis,F., Ambrosio,A.F. and Fernandes,R.
    Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model
    Diabetes Obes Metab (2012) 14, 454-463. PubMed  Europe PubMed DOI  I
  62. Hong,E.S., Khang,A.R., Yoon,J.W., Kang,S.M., Choi,S.H., Park,K.S., Jang,H.C., Shin,H., Walford,G.A. and Lim,S.
    Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study
    Diabetes Obes Metab (2012) 14, 795-802. PubMed  Europe PubMed DOI  I
  63. Huang,C.Y., Shih,C.M., Tsao,N.W., Lin,Y.W., Huang,P.H., Wu,S.C., Lee,A.W., Kao,Y.T., Chang,N.C., Nakagami,H., Morishita,R., Ou,K.L., Hou,W.C., Lin,C.Y., Shyu,K.G. and Lin,F.Y.
    Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
    Br J Pharmacol (2012) 167, 1506-1519. PubMed  Europe PubMed DOI  I
  64. Kandasamy,N., Lennox,G., Annamalai,A.K., Maguire,G. and Adler,A.I.
    Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus
    Endocr Pract (2012) 18, e65-e68. PubMed  Europe PubMed DOI  I
  65. Kim,D.H., Huh,J.W., Jang,M., Suh,J.H., Kim,T.W., Park,J.S. and Yoon,S.Y.
    Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures
    Neurobiol Dis (2012) 46, 52-58. PubMed  Europe PubMed DOI  I
  66. Kubota,A., Maeda,H., Kanamori,A., Matoba,K., Jin,Y., Minagawa,F., Obana,M., Iemitsu,K., Ito,S., Amemiya,H., Kaneshiro,M., Takai,M., Kaneshige,H., Hoshino,K., Ishikawa,M., Minami,N., Takuma,T., Sasai,N., Aoyagi,S., Kawata,T., Mokubo,A., Takeda,H., Honda,S., Machimura,H., Motomiya,T., Waseda,M., Naka,Y., Tanaka,Y., Terauchi,Y. and Matsuba,I.
    Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients
    J Clin Med Res (2012) 4, 309-313. PubMed  Europe PubMed DOI  PMC  EPMC  I
  67. Kubota,Y., Miyamoto,M., Takagi,G., Ikeda,T., Kirinoki-Ichikawa,S., Tanaka,K. and Mizuno,K.
    The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes
    J Korean Med Sci (2012) 27, 1364-1370. PubMed  Europe PubMed DOI  PMC  EPMC  I
  68. Lim,S., Choi,S.H., Shin,H., Cho,B.J., Park,H.S., Ahn,B.Y., Kang,S.M., Yoon,J.W., Jang,H.C., Kim,Y.B. and Park,K.S.
    Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats
    PLoS ONE (2012) 7, e35007-e35007. PubMed  Europe PubMed DOI  PMC  EPMC  I
  69. Makdissi,A., Ghanim,H., Vora,M., Green,K., Abuaysheh,S., Chaudhuri,A., Dhindsa,S. and Dandona,P.
    Sitagliptin exerts an antinflammatory action
    J Clin Endocrinol Metab (2012) 97, 3333-3341. PubMed  Europe PubMed DOI  I
  70. Matsubara,J., Sugiyama,S., Sugamura,K., Nakamura,T., Fujiwara,Y., Akiyama,E., Kurokawa,H., Nozaki,T., Ohba,K., Konishi,M., Maeda,H., Izumiya,Y., Kaikita,K., Sumida,H., Jinnouchi,H., Matsui,K., Kim-Mitsuyama,S., Takeya,M. and Ogawa,H.
    A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice
    J Am Coll Cardiol (2012) 59, 265-276. PubMed  Europe PubMed DOI  I
  71. Matsuhashi,T., Sano,M., Fukuda,K., Kohsaka,S. and Suzuki,Y.
    Sitagliptin counteracts seasonal fluctuation of glycemic control
    World J Diabetes (2012) 3, 118-122. PubMed  Europe PubMed DOI  PMC  EPMC  I
  72. Monami,M., Lamanna,C., Desideri,C.M. and Mannucci,E.
    DPP-4 Inhibitors and lipids: systematic review and meta-analysis
    Adv Ther (2012) 29, 14-25. PubMed  Europe PubMed DOI  I
  73. Nader,M.A., El-Awady,M.S., Shalaby,A.A. and El-Agamy,D.S.
    Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease
    Naunyn Schmiedebergs Arch Pharmacol (2012) 385, 909-919. PubMed  Europe PubMed DOI  I
  74. Nishioka,T., Shinohara,M., Tanimoto,N., Kumagai,C. and Hashimoto,K.
    Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis
    Dermatology (2012) 224, 20-21. PubMed  Europe PubMed DOI  I
  75. Nomiyama,T., Akehi,Y., Takenoshita,H., Nagaishi,R., Terawaki,Y., Nagasako,H., Kudo,T., Kodera,T., Kobayashi,K., Urata,H. and Yanase,T.
    Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Diabetes Res Clin Pract (2012) 95, e27-e28. PubMed  Europe PubMed DOI  I
  76. Poucher,S.M., Cheetham,S., Francis,J., Zinker,B., Kirby,M. and Vickers,S.P.
    Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic beta-cell mass in a streptozotocin-induced mouse model of type 2 diabetes
    Diabetes Obes Metab (2012) 14, 918-926. PubMed  Europe PubMed DOI  I
  77. Stevens,J.E., Horowitz,M., Deacon,C.F., Nauck,M., Rayner,C.K. and Jones,K.L.
    The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study
    Aliment Pharmacol Ther (2012) 36, 379-390. PubMed  Europe PubMed DOI  I
    78. 2011
  78. Baetta,R. and Corsini,A.
    Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
    Drugs (2011) 71, 1441-1467. PubMed  Europe PubMed DOI  I
  79. Elashoff,M., Matveyenko,A.V., Gier,B., Elashoff,R. and Butler,P.C.
    Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
    Gastroenterology (2011) 141, 150-156. PubMed  Europe PubMed DOI  I
  80. Ellis,S.L., Moser,E.G., Snell-Bergeon,J.K., Rodionova,A.S., Hazenfield,R.M. and Garg,S.K.
    Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
    Diabet Med (2011) 28, 1176-1181. PubMed  Europe PubMed DOI  I
  81. Gupta,V. and Kalra,S.
    Choosing a gliptin
    Indian J Endocrinol Metab (2011) 15, 298-308. PubMed  Europe PubMed DOI  PMC  EPMC  I
  82. Herman,G.A., Mistry,G.C., Yi,B., Bergman,A.J., Wang,A.Q., Zeng,W., Chen,L., Snyder,K., Ruckle,J.L., Larson,P.J., Davies,M.J., Langdon,R.B., Gottesdiener,K.M. and Wagner,J.A.
    Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
    Br J Clin Pharmacol (2011) 71, 429-436. PubMed  Europe PubMed DOI  I
  83. Ishibashi,Y., Matsui,T., Takeuchi,M. and Yamagishi,S.
    Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells
    Horm Metab Res (2011) 43, 731-734. PubMed  Europe PubMed DOI  I
  84. Jermendy,G.
    [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]
    Orv Hetil (2011) 152, 1471-1476. PubMed  Europe PubMed DOI  V  I
  85. Kalra,S., Unnikrishnan,A.G., Agrawal,N. and Singh,A.K.
    Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications
    Recent Pat Endocr Metab Immune Drug Discov (2011) 5, 197-202. PubMed  Europe PubMed DOI  I
  86. Kutoh,E.
    Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
    J Med Case Reports (2011) 5, 117-117. PubMed  Europe PubMed DOI  I
  87. Mega,C., Teixeira de Lemos,E., Vala,H., Fernandes,R., Oliveira,J., Mascarenhas-Melo,F., Teixeira,F. and Reis,F.
    Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (zucker diabetic Fatty rat)
    Exp Diabetes Res (2011) 2011, 162092-162092. PubMed  Europe PubMed DOI  PMC  EPMC  I
  88. Mori,Y., Taniguchi,Y., Matsuura,K., Sezaki,K., Yokoyama,J. and Utsunomiya,K.
    Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring
    Diabetes Technol Ther (2011) 13, 699-703. PubMed  Europe PubMed DOI  I
  89. Nagamatsu,S., Ohara-Imaizumi,M., Nakamichi,Y., Aoyagi,K. and Nishiwaki,C.
    DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice beta cells
    Biochem Biophys Res Commun (2011) 412, 556-560. PubMed  Europe PubMed DOI  I
  90. Ogawa,S., Ishiki,M., Nako,K., Okamura,M., Senda,M., Mori,T. and Ito,S.
    Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes
    Tohoku J Exp Med (2011) 223, 133-135. PubMed  Europe PubMed DOI  I
  91. Okawada,M., Holst,J.J. and Teitelbaum,D.H.
    Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome
    Surgery (2011) 150, 217-223. PubMed  Europe PubMed DOI  I
  92. Onishi,K.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes accompanied with cardiovascular disease
    Ther Res (2011) 32, 835-840.  I
  93. Pitocco,D., Zaccardi,F., Martini,F., Scavone,G., Musella,T., Caputo,S. and Ghirlanda,G.
    Severe leucopenia associated with sitagliptin use
    Diabetes Res Clin Pract (2011) 91, e30-e32. PubMed  Europe PubMed DOI  I
  94. Rabasseda,X.
    [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)]
    Drugs Today (Barc) (2011) 47 Suppl D, 1-8. PubMed  Europe PubMed DOI  I
  95. Richard,K.R., Shelburne,J.S. and Kirk,J.K.
    Tolerability of dipeptidyl peptidase-4 inhibitors: a review
    Clin Ther (2011) 33, 1609-1629. PubMed  Europe PubMed DOI  V  I
  96. Sayo,Y. and Ishiko,T.
    Clinical efficacy of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes for 6 months
    Ther Res (2011) 32, 523-529.  I
  97. Signorovitch,J.E., Wu,E.Q., Swallow,E., Kantor,E., Fan,L. and Gruenberger,J.B.
    Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
    Clin Drug Investig (2011) 31, 665-674. PubMed  Europe PubMed DOI  I
  98. Stafford,S., Elahi,D. and Meneilly,G.S.
    Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus
    J Am Geriatr Soc (2011) 59, 1148-1149. PubMed  Europe PubMed DOI  I
  99. Subbarayan,S. and Kipnes,M.
    Sitagliptin: a review
    Expert Opin Pharmacother (2011) 12, 1613-1622. PubMed  Europe PubMed DOI  V  I
  100. Waget,A., Cabou,C., Masseboeuf,M., Cattan,P., Armanet,M., Karaca,M., Castel,J., Garret,C., Payros,G., Maida,A., Sulpice,T., Holst,J.J., Drucker,D.J., Magnan,C. and Burcelin,R.
    Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice
    Endocrinology (2011) 152, 3018-3029. PubMed  Europe PubMed DOI  I
    101. 2010
  101. Davis,J., Singh,S., Sethi,S., Roy,S., Mittra,S., Rayasam,G., Bansal,V., Sattigeri,J. and Ray,A.
    Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
    Indian J Pharmacol (2010) 42, 229-233. PubMed  Europe PubMed DOI  I
  102. Dhillon,S.
    Sitagliptin: a review of its use in the management of type 2 diabetes mellitus
    Drugs (2010) 70, 489-512. PubMed  Europe PubMed DOI  V  I
  103. Gerich,J.
    DPP-4 inhibitors: What may be the clinical differentiators?
    Diabetes Res Clin Pract (2010) 90, 131-140. PubMed  Europe PubMed DOI  V  I
  104. Iwamoto,Y., Taniguchi,T., Nonaka,K., Okamoto,T., Okuyama,K., Ferreira,J.C. and Amatruda,J.
    Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
    Endocr J (2010) 57, 383-394. PubMed  Europe PubMed DOI  I
  105. Kim,S.J., Nian,C. and McIntosh,C.H.
    Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-Cell migration through incretin-dependent and -independent pathways
    Diabetes (2010) 59, 1739-1750. PubMed  Europe PubMed DOI  I
  106. Liu,F., Yu,W., Ou,W., Wang,X., Ruan,L., Li,Y., Peng,X., Tao,X. and Pan,X.
    The asymmetric synthesis of sitagliptin, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    J Chem Res (2010) 2010, 230-232.  I
  107. Sauve,M., Ban,K., Momen,M.A., Zhou,Y.Q., Henkelman,R.M., Husain,M. and Drucker,D.J.
    Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
    Diabetes (2010) 59, 1063-1073. PubMed  Europe PubMed DOI  K  I
  108. Scheen,A.J., Charpentier,G., Ostgren,C.J., Hellqvist,A. and Gause-Nilsson,I.
    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    Diabetes Metab Res Rev (2010) 26, 540-549. PubMed  Europe PubMed DOI  I
  109. Tofovic,D.S., Bilan,V.P. and Jackson,E.K.
    Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome
    Clin Exp Pharmacol Physiol (2010) 37, 689-691. PubMed  Europe PubMed DOI  I
  110. White,P.C., Chamberlain-Shea,H. and de la Morena,M.T.
    Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation
    J Diabetes Complications (2010) 24, 209-213. PubMed  Europe PubMed DOI  I
    111. 2009
  111. Alba,M., Sheng,D., Guan,Y., Williams-Herman,D., Larson,P., Sachs,J.R., Thornberry,N., Herman,G., Kaufman,K.D. and Goldstein,B.J.
    Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
    Curr Med Res Opin (2009) 25, 2507-2514. PubMed  Europe PubMed DOI  I
  112. Argyrakopoulou,G. and Doupis,J.
    DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
    Adv Ther (2009) 26, 272-280. PubMed  Europe PubMed DOI  I
  113. Migoya,E.M., Stevens,C.H., Bergman,A.J., Luo,W.L., Lasseter,K.C., Dilzer,S.C., Davies,M.J., Wagner,J.A. and Herman,G.A.
    Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin
    Can J Clin Pharmacol (2009) 16, e165-e170. PubMed  Europe PubMed  I
  114. Thornberry,N.A. and Gallwitz,B.
    Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
    Best Pract Res Clin Endocrinol Metab (2009) 23, 479-486. PubMed  Europe PubMed DOI  I
    115. 2008
  115. Nonaka,K., Kakikawa,T., Sato,A., Okuyama,K., Fujimoto,G., Kato,N., Suzuki,H., Hirayama,Y., Ahmed,T., Davies,M.J. and Stein,P.P.
    Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
    Diabetes Res Clin Pract (2008) 79, 291-298. PubMed  Europe PubMed DOI  I
  116. Pei,Z.
    From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents
    Curr Opin Drug Discov Devel (2008) 11, 512-532. PubMed  Europe PubMed  I
  117. Pham,D.Q., Nogid,A. and Plakogiannis,R.
    Sitagliptin: a novel agent for the management of type 2 diabetes mellitus
    Am J Health Syst Pharm (2008) 65, 521-531. PubMed  Europe PubMed DOI  I
  118. Wani,J.H., John-Kalarickal,J. and Fonseca,V.A.
    Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review
    Cardiol Clin (2008) 26, 639-648. PubMed  Europe PubMed DOI  V  I
  119. Williams-Herman,D., Round,E., Swern,A.S., Musser,B., Davies,M.J., Stein,P.P., Kaufman,K.D. and Amatruda,J.M.
    Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
    BMC Endocr Disord (2008) 8, 14-14. PubMed  Europe PubMed DOI  PMC  EPMC  I
    120. 2007
  120. Bergman,A., Mistry,G.C., Luo,W.L., Liu,Q., Stone,J., Wang,A., Zeng,W., Chen,L., Dilzer,S., Lasseter,K., Herman,G.A., Wagner,J.A. and Krishna,R.
    Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Biopharm Drug Dispos (2007) 28, 307-313. PubMed  Europe PubMed DOI  I
  121. Bergman,A., Ebel,D., Liu,F., Stone,J., Wang,A., Zeng,W., Chen,L., Dilzer,S., Lasseter,K., Herman,G., Wagner,J. and Krishna,R.
    Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Biopharm Drug Dispos (2007) 28, 315-322. PubMed  Europe PubMed DOI  I
  122. Biftu,T., Feng,D., Qian,X., Liang,G.B., Kieczykowski,G., Eiermann,G., He,H., Leiting,B., Lyons,K., Petrov,A., Sinha-Roy,R., Zhang,B., Scapin,G., Patel,S., Gao,Y.D., Singh,S., Wu,J., Zhang,X., Thornberry,N.A. and Weber,A.E.
    (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoro ethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Bioorg Med Chem Lett (2007) 17, 49-52. PubMed  Europe PubMed DOI  I
  123. Biftu,T., Scapin,G., Singh,S., Feng,D., Becker,J.W., Eiermann,G., He,H., Lyons,K., Patel,S., Petrov,A., Sinha-Roy,R., Zhang,B., Wu,J., Zhang,X., Doss,G.A., Thornberry,N.A. and Weber,A.E.
    Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
    Bioorg Med Chem Lett (2007) 17, 3384-3387. PubMed  Europe PubMed DOI  S  I
  124. Choy,M. and Lam,S.
    Sitagliptin: a novel drug for the treatment of type 2 diabetes
    Cardiol Rev (2007) 15, 264-271. PubMed  Europe PubMed DOI  I
  125. Deacon,C.F.
    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
    Expert Opin Investig Drugs (2007) 16, 533-545. PubMed  Europe PubMed DOI  I
  126. Gallwitz,B.
    Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
    Drugs Today (Barc) (2007) 43, 13-25. PubMed  Europe PubMed DOI  I
  127. Gallwitz,B.
    Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
    Drugs Today (Barc) (2007) 43, 801-814. PubMed  Europe PubMed DOI  V  I
  128. Gallwitz,B.
    Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
    Vasc Health Risk Manag (2007) 3, 203-210. PubMed  Europe PubMed DOI  PMC  EPMC  V  I
  129. Goldstein,B.J., Feinglos,M.N., Lunceford,J.K., Johnson,J. and Williams-Herman,D.E.
    Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    Diabetes Care (2007) 30, 1979-1987. PubMed  Europe PubMed DOI  I
  130. Hanefeld,M., Herman,G.A., Wu,M., Mickel,C., Sanchez,M. and Stein,P.P.
    Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Curr Med Res Opin (2007) 23, 1329-1339. PubMed  Europe PubMed DOI  I
  131. Herman,G.A., Stein,P.P., Thornberry,N.A. and Wagner,J.A.
    Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin
    Clin Pharmacol Ther (2007) 81, 761-767. PubMed  Europe PubMed DOI  I
  132. Hermansen,K., Kipnes,M., Luo,E., Fanurik,D., Khatami,H. and Stein,P.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    Diabetes Obes Metab (2007) 9, 733-745. PubMed  Europe PubMed DOI  I
  133. Kim,D., Kowalchick,J.E., Edmondson,S.D., Mastracchio,A., Xu,J., Eiermann,G.J., Leiting,B., Wu,J.K., Pryor,K.D., Patel,R.A., He,H., Lyons,K.A., Thornberry,N.A. and Weber,A.E.
    Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate)
    Bioorg Med Chem Lett (2007) 17, 3373-3377. PubMed  Europe PubMed DOI  I
  134. Liu,D.Q., Arison,B.H., Stearns,R.A., Kim,D. and Vincent,S.H.
    Characterization of two cyclic metabolites of sitagliptin
    Drug Metab Dispos (2007) 35, 521-524. PubMed  Europe PubMed DOI  I
  135. Lyseng-Williamson,K.A.
    Sitagliptin
    Drugs (2007) 67, 587-597. PubMed  Europe PubMed DOI  V  I
  136. Scott,R., Wu,M., Sanchez,M. and Stein,P.
    Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
    Int J Clin Pract (2007) 61, 171-180. PubMed  Europe PubMed DOI  I
  137. Thornberry,N.A. and Weber,A.E.
    Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Curr Top Med Chem (2007) 7, 557-568. PubMed  Europe PubMed DOI  I
  138. Vincent,S.H., Reed,J.R., Bergman,A.J., Elmore,C.S., Zhu,B., Xu,S., Ebel,D., Larson,P., Zeng,W., Chen,L., Dilzer,S., Lasseter,K., Gottesdiener,K., Wagner,J.A. and Herman,G.A.
    Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [ 14C]sitagliptin in humans
    Drug Metab Dispos (2007) 35, 533-538. PubMed  Europe PubMed DOI  I
  139. Zerilli,T. and Pyon,E.Y.
    Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Clin Ther (2007) 29, 2614-2634. PubMed  Europe PubMed DOI  V  I
    140. 2006
  140. Aschner,P., Kipnes,M.S., Lunceford,J.K., Sanchez,M., Mickel,C. and Williams-Herman,D.E.
    Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Diabetes Care (2006) 29, 2632-2637. PubMed  Europe PubMed DOI  I
  141. Barnett,A.
    DPP-4 inhibitors and their potential role in the management of type 2 diabetes
    Int J Clin Pract (2006) 60, 1454-1470. PubMed  Europe PubMed DOI  V  I
  142. Bergman,A.J., Stevens,C., Zhou,Y., Yi,B., Laethem,M., De Smet,M., Snyder,K., Hilliard,D., Tanaka,W., Zeng,W., Tanen,M., Wang,A.Q., Chen,L., Winchell,G., Davies,M.J., Ramael,S., Wagner,J.A. and Herman,G.A.
    Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers
    Clin Ther (2006) 28, 55-72. PubMed  Europe PubMed DOI  I
  143. [YEAR:23-8-2006]Herman,G.A., Bergman,A., Stevens,C., Kotey,P., Yi,B., Zhao,P., Dietrich,B., Golor,G., Schrodter,A., Keymeulen,B., Lasseter,K.C., Kipnes,M.S., Snyder,K., Hilliard,D., Tanen,M., Cilissen,C., De Smet,M., de Lepeleire,I., Van Dyck,K., Wang,A.Q., Zeng,W., Davies,M.J., Tanaka,W., Holst,J.J., Deacon,C.F., Gottesdiener,K.M. and Wagner,J.A.
    Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    J Clin Endocrinol Metab (23-8-2006) 91, 4612-4619. PubMed  Europe PubMed DOI  I
  144. Herman,G.A., Bergman,A., Liu,F., Stevens,C., Wang,A.Q., Zeng,W., Chen,L., Snyder,K., Hilliard,D., Tanen,M., Tanaka,W., Meehan,A.G., Lasseter,K., Dilzer,S., Blum,R. and Wagner,J.A.
    Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects
    J Clin Pharmacol (2006) 46, 876-886. PubMed  Europe PubMed DOI  I
  145. [YEAR:25-7-2006]Miller,S. and St Onge,E.L.
    Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Ann Pharmacother (25-7-2006) 40, 1336-1343. PubMed  Europe PubMed DOI  I
  146. Mu,J., Woods,J., Zhou,Y.P., Roy,R.S., Li,Z., Zycband,E., Feng,Y., Zhu,L., Li,C., Howard,A.D., Moller,D.E., Thornberry,N.A. and Zhang,B.B.
    Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
    Diabetes (2006) 55, 1695-1704. PubMed  Europe PubMed DOI  I
  147. [YEAR:26-9-2006]Raz,I., Hanefeld,M., Xu,L., Caria,C., Williams-Herman,D. and Khatami,H.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Diabetologia (26-9-2006) 49, 2564-2571. PubMed  Europe PubMed DOI  I
  148. Rosenstock,J., Brazg,R., Andryuk,P.J., Lu,K. and Stein,P.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    Clin Ther (2006) 28, 1556-1568. PubMed  Europe PubMed DOI  I
  149. Schlesselman,L.S.
    Sitagliptin: The first dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Formulary (2006) 41, 434-441.  I
    150. 2005
  150. Herman,G.A., Stevens,C., Van Dyck,K., Bergman,A., Yi,B., De Smet,M., Snyder,K., Hilliard,D., Tanen,M., Tanaka,W., Wang,A.Q., Zeng,W., Musson,D., Winchell,G., Davies,M.J., Ramael,S., Gottesdiener,K.M. and Wagner,J.A.
    Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
    Clin Pharmacol Ther (2005) 78, 675-688. PubMed  Europe PubMed DOI  I
  151. [YEAR:13-1-2005]Kim,D., Wang,L., Beconi,M., Eiermann,G.J., Fisher,M.H., He,H., Hickey,G.J., Kowalchick,J.E., Leiting,B., Lyons,K., Marsilio,F., McCann,M.E., Patel,R.A., Petrov,A., Scapin,G., Patel,S.B., Roy,R.S., Wu,J.K., Wyvratt,M.J., Zhang,B.B., Zhu,L., Thornberry,N.A. and Weber,A.E.
    (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    J Med Chem (13-1-2005) 48, 141-151. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use